Medicamen Biotech Ltd, incorporated in 1993, is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations. MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals.
Medicamen Biotech Limited researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations and APIs in India. The company offers a range of products, including tablets, such as non-beta lactam tablets; capsules comprising beta and non-beta lactam capsules; liquid and dry syrups; and ointments and creams. The company's products are used in various therapeutic areas, such as gastrointestinal, pain management, anti-infectives, pediatrics, dermatology, gynecology and rheumatology, diabetology, cardiology, oncology, and the central nervous system.
The company's formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets. The Company is engaged in the manufacturing of a diverse range of pharmaceutical products: oral solids, oral liquids, and ointments for non-oncology products, and also produces tablets, capsules, lyophilized/dry powder injections for oncology product range. It focuses on oncology therapeutics and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, and dry syrup, such as beta-lactam and non-beta lactam, and ointments.
The Company launched 12 Oncology products in the domestic market effective from January 2022. This strategic focus on oncology positions Medicamen Biotech as a specialized player in the high-value cancer therapeutics segment, which represents a growing market opportunity both domestically and internationally.
The company has achieved significant regulatory milestones that enhance its credibility and market access. Medicamen received its first USFDA ANDA approval for Bortezomib injection 3.5 mg, enabling US market entry. This marks a crucial achievement for the company as it opens doors to the lucrative US pharmaceutical market.
Medicamen Biotech is proud to announce that its state-of-the-art manufacturing facility in Bhiwadi, Rajasthan, has achieved European Union Good Manufacturing Practice (EU GMP) certification from the National Organisation for Medicines in Athens, Greece. Additionally, the company's Sterile Oncology Facility is now USFDA approved, enabling expansion into regulated markets like the US and the Middle East. This milestone reflects their commitment to delivering high-quality oncology treatments globally, supporting patients with advanced, compliant options.
The company has a market cap of ₹580 Cr as of 07-May-2025.
For FY25 financial performance, the company's consolidated net profit rose 13.6% to Rs 2.42 crore in Q4 FY25, despite a 37.4% decline in revenue from operations to Rs 29.61 crore compared to the year-ago period. The company has shown mixed performance with revenue of ₹163 Cr and profit of ₹6.56 Cr for the full year.
However, the company faces some financial challenges. The company has delivered a poor sales growth of 5.31% over the past five years. Additionally, the Company has a low return on equity of 5.31% over the last 3 years.
- Q4 FY25 Performance: Consolidated Net Profit of Rs 2.42 crore (up 13.6%), Revenue from operations of Rs 29.61 crore (down 37.4%)
- Full Year FY25 Performance: Revenue of ₹163 Cr, Profit of ₹6.56 Cr
- Market Capitalization: ₹580 Cr (as of 07-May-2025)
- Promoter Holding: 40.5%
- PE Ratio: 64.80 (as of May 27, 2025)
- PB Ratio: 0.40 (as of May 27, 2025)
- Dividend: 10% final dividend approved for FY25
Medicamen Lifesciences, a subsidiary of MEDICAMEN BIOTECH, officially launched operations in 2022. The company specializes in the manufacturing and marketing of pharmaceutical products, with a focus on Anti-hypertensives, Antidiabetics, and Cardiology treatments.
Shivalik Rasayan Ltd., the parent company of Medicamen, has successfully obtained USFDA Approval for its state-of-the-art global API manufacturing facility. This approval strengthens the company's backward integration capabilities and quality credentials.
Looking ahead, the company is optimistic about receiving USFDA approval for its Oncology Plant, which will unlock significant opportunities in regulated markets, particularly in the US and Middle East.
The 52-week low for Medicamen Biotech share price was Rs. 375.05 and the 52-week high was Rs. 630.00. Over the past 6 months, the Medicamen Biotech share price has decreased by 2.99%, and in the last one year, it has decreased by 18%. Medicamen Biotech Ltd has given a return of -14.58% in the last 3 years.
The company's stock trades on both NSE and BSE under the symbol MEDICAMEQ, providing liquidity and accessibility to investors across different market segments. Despite recent price volatility, the company's focused strategy on oncology and its recent regulatory approvals position it for potential growth in specialized pharmaceutical segments.
